Health Economics›Classical Hodgkin lymphoma›Untreated early-stage favorable (ESF)

Untreated early-stage favorable (ESF)

Classical Hodgkin lymphoma · 6 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Stanford V Variant #01 Partial	—	R 18 121	28d	—	—	1	R 18 121 PFS proxy	1
AVD Variant #01	—	R 5 770	28d	—	—	~4	~R 23 082 indirect	—
ABVD Variant #01 Partial	—	R 2 885	28d	—	—	2	R 5 770 PFS proxy	4
MOPP-ABV Variant #01 Partial	—	R 2 205	28d	—	—	~4	~R 8 819 indirect	—
Observation Partial	—	—	—	—	—	—	—	1
Radiation therapy N/A - radiation	—	—	49d	—	—	—	—	1

6 of 6 regimens shown